Pharmaceutical company Cingulate Inc. (CING), Friday announced the pricing of 3.75 million shares at $2 per share, to raise $7.5 million.
The company said that it intends to use the proceeds from the offering for the development and commercialization of its lead candidate CTx-1301 and other corporate-related purposes.
The company also announced accompanying warrants of Series A to purchase up to 3.75 shares and Series B to purchase up to 1.875 shares.
Both warrants will be exercised immediately for $2 per share. However, Series A warrants and Series B warrants will expire in five and two years, respectively, from their date of issuance.
The offering will close on or about February 6.
H.C. Wainwright & Co. acts as the placement agent of the offering.
Following the announcement, Cingulate's stock is tanking 45.92 percent, to $1.82 over the previous close of $3.36 on a volume of 842,188 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.